<p>Travere Therapeutics, Inc.（纳斯达克代码：TVTX - 获取免费报告）首席执行官 Eric Dube 于 1 月 23 日（星期五）出售了 8,135 股公司股票。股票的平均售价为 30.01 美元，总交易额为 244,131.35 美元。交易完成后，首席执行官持有公司 419,173 股股票，价值为 12,579,381.73 美元。此次交易代表其持股比例减少了 1.90%。该交易已在向美国证券交易委员会（SEC）的备案中披露，相关信息可通过此链接获取。</p>
<p>获取 <strong>Travere Therapeutics</strong> 的提醒：</p>
<h2>Travere Therapeutics 价格表现</h2>
<ul>
<li>3 家不为人知的医疗公司</li>
</ul>
<p>在周二的午盘交易中，纳斯达克：TVTX 上涨 0.09 美元，达到 30.03 美元。公司股票交易量为 1,424,711 股，而其平均交易量为 2,922,582 股。Travere Therapeutics, Inc. 的一年最低价为 12.91 美元，一年最高价为 42.13 美元。该公司的债务与股本比率为 4.23，流动比率为 2.75，速动比率为 2.71。该公司的 50 日简单移动平均线为 34.58 美元，200 日简单移动平均线为 27.12 美元。</p>
<p>Travere Therapeutics（纳斯达克：TVTX - 获取免费报告）最近于 10 月 30 日（星期四）公布了其财报。公司报告本季度每股收益（EPS）为 0.28 美元，超出分析师一致预期的（0.31 美元）0.59 美元。Travere Therapeutics 的净利润率为-20.32%，股本回报率为-178.68%。该公司本季度的收入为 1.6486 亿美元，而分析师预期为 1.0609 亿美元。去年同期，该公司的每股收益为（0.70 美元）。与去年同期相比，该公司的收入增长了 162.1%。分析师预测 Travere Therapeutics, Inc.在当前年度的每股收益将为-1.4 美元。</p>
<h2>机构投资者对 Travere Therapeutics 的看法</h2>
<ul>
<li>Travere Therapeutics 在鼓舞人心的数据后仍在上升</li>
</ul>
<p>几家对冲基金最近增加或减少了对 TVTX 的持股。First Horizon Corp 在第三季度购买了价值约 36,000 美元的 Travere Therapeutics 新股份。Raymond James Financial Inc.在第二季度购买了价值约 33,000 美元的 Travere Therapeutics 新头寸。Mirae Asset Global Investments Co. Ltd.在第四季度将其在 Travere Therapeutics 的持股增加了 26.2%。Mirae Asset Global Investments Co. Ltd.现在拥有 4,348 股公司股票，价值 166,000 美元，此前在此期间又购买了 902 股。Headlands Technologies LLC 在第二季度购买了价值约 73,000 美元的 Travere Therapeutics 新股份。最后，Wealth Enhancement Advisory Services LLC 在第四季度购买了价值约 224,000 美元的 Travere Therapeutics 新股份。</p>
<h2>分析师的升级和降级</h2>
<p>几家研究公司最近对 TVTX 发表了评论。Weiss Ratings 在 1 月 21 日（星期三）的研究报告中重申了对 Travere Therapeutics 股票的 “卖出（e+）” 评级。Zacks Research 在 11 月 12 日（星期三）的研究报告中将 Travere Therapeutics 的股票评级从 “强力买入” 下调至 “持有”。HC Wainwright 在 11 月 28 日（星期五）的研究报告中重申了 “买入” 评级，并设定了 47.00 美元的目标价。Guggenheim 在 1 月 14 日（星期三）的研究报告中重申了 “买入” 评级，并对 Travere Therapeutics 的股票设定了 49.00 美元的目标价。最后，Wall Street Zen 在 12 月 13 日（星期六）的报告中将 Travere Therapeutics 的评级从 “买入” 升级为 “强力买入”。十二位投资分析师对该股票给予了买入评级，三位给予了持有评级，一位给予了卖出评级。根据 MarketBeat.com 的数据，Travere Therapeutics 的共识评级为 “适度买入”，共识目标价为 38.86 美元。</p>
<p><strong>查看我们关于 TVTX 的最新报告</strong></p>
<h2>关于 Travere Therapeutics</h2>
<p>（获取免费报告）</p>
<p>Travere Therapeutics, Inc.（纳斯达克：TVTX）是一家总部位于加利福尼亚州圣地亚哥的生物制药公司，致力于开发和商业化针对罕见肾脏和遗传疾病的疗法。公司的使命是通过关注影响小型患者群体的疾病，解决治疗选择有限的疾病的未满足需求。Travere 结合了研究、开发和商业能力，将创新药物推向市场。</p>
<p>公司的主要产品是 sparsentan，这是一种双重内皮素 - 血管紧张素受体拮抗剂，已获得美国的加速批准。</p>
<h2>了解更多</h2>
<ul>
<li>我们更看好的五只股票比 Travere Therapeutics 更好</li>
<li>家族信托如何帮助保护您的财富</li>
<li>请勿删除，立即阅读</li>
<li>新法律：国会批准数字美元的设立？</li>
<li>用这 4 个简单步骤 “防止” 您的银行账户受到影响</li>
<li>一项价值数万亿的美国 “出生权” 索赔 - 静悄悄地激活</li>
</ul>
<p><img src="https://imageproxy.pbkrs.com/https://www.marketbeat.com/scripts/InsiderTradesChart.ashx/query-UHJlZml4PU5BU0RBUSZTeW1ib2w9VFZUWA?x-oss-process=image/auto-orient,1/interlace,1/resize,w_1440,h_1440/quality,q_95/format,jpg" alt="" original-src="https://imageproxy.pbkrs.com/https://www.marketbeat.com/scripts/InsiderTradesChart.ashx/query-UHJlZml4PU5BU0RBUSZTeW1ib2w9VFZUWA"/></p>
<p><em>此即时新闻提醒由叙述科学技术和 MarketBeat 的金融数据生成，以便为读者提供最快的报道和公正的覆盖。请将任何问题或评论发送至 contact@marketbeat.com。</em></p>
<h2>您现在应该投资 1,000 美元于 Travere Therapeutics 吗？</h2>
<p>在您考虑 Travere Therapeutics 之前，您需要听听这个。</p>
<p>MarketBeat 每天跟踪华尔街顶级评级和表现最佳的研究分析师及其推荐的股票。MarketBeat 已识别出五只股票，顶级分析师正在悄悄地向客户推荐在更广泛的市场注意到之前立即购买……而 Travere Therapeutics 并不在名单上。</p>
<p>虽然 Travere Therapeutics 目前在分析师中获得了适度买入评级，但顶级分析师认为这五只股票更值得购买。</p>
<p>在这里查看这五只股票</p>

TVTX

<p>Travere Therapeutics 首席执行官 Eric Dube 出售了 8,135 股公司股票，交易金额为 244,131.35 美元，平均价格为 30.01 美元，减少了 1.90% 的持股比例。出售后，他持有 419,173 股，价值约为 1258 万美元。该交易已向美国证券交易委员会（SEC）披露。Travere 的股票交易价格为 30.03 美元，过去一年价格区间为 12.91 至 42.13 美元。公司报告的季度收入同比增长 162.1%，达到 1.6486 亿美元，每股收益（EPS）为 0.28 美元，超出预期。分析师维持 “适度买入” 的共识评级，目标价格为 38.86 美元</p>

<p>Travere Therapeutics, Inc. (NASDAQ:TVTX - Get Free Report) CEO Eric Dube sold 8,135 shares of the company's stock in a transaction dated Friday, January 23rd. The shares were sold at an average price of $30.01, for a total transaction of $244,131.35. Following the completion of the transaction, the chief executive officer owned 419,173 shares in the company, valued at $12,579,381.73. This trade represents a 1.90% decrease in their ownership of the stock. The transaction was disclosed in a filing with the SEC, which is available through this hyperlink.</p>
<div class="lb-trans"><p>Travere Therapeutics, Inc.（纳斯达克代码：TVTX - 获取免费报告）首席执行官 Eric Dube 于 1 月 23 日（星期五）出售了 8,135 股公司股票。股票的平均售价为 30.01 美元，总交易额为 244,131.35 美元。交易完成后，首席执行官持有公司 419,173 股股票，价值为 12,579,381.73 美元。此次交易代表其持股比例减少了 1.90%。该交易已在向美国证券交易委员会（SEC）的备案中披露，相关信息可通过此链接获取。</p>
</div><p>Get <strong>Travere Therapeutics</strong> alerts:</p>
<div class="lb-trans"><p>获取 <strong>Travere Therapeutics</strong> 的提醒：</p>
</div><h2>Travere Therapeutics Price Performance</h2>
<div class="lb-trans"><h2>Travere Therapeutics 价格表现</h2>
</div><ul>
<li>3 Under-the-Radar Healthcare Companies</li>
</ul>
<div class="lb-trans"><ul>
<li>3 家不为人知的医疗公司</li>
</ul>
</div><p>NASDAQ:TVTX traded up $0.09 during mid-day trading on Tuesday, reaching $30.03. 1,424,711 shares of the company's stock were exchanged, compared to its average volume of 2,922,582. Travere Therapeutics, Inc. has a one year low of $12.91 and a one year high of $42.13. The company has a debt-to-equity ratio of 4.23, a current ratio of 2.75 and a quick ratio of 2.71. The business's fifty day simple moving average is $34.58 and its two-hundred day simple moving average is $27.12.</p>
<div class="lb-trans"><p>在周二的午盘交易中，纳斯达克：TVTX 上涨 0.09 美元，达到 30.03 美元。公司股票交易量为 1,424,711 股，而其平均交易量为 2,922,582 股。Travere Therapeutics, Inc. 的一年最低价为 12.91 美元，一年最高价为 42.13 美元。该公司的债务与股本比率为 4.23，流动比率为 2.75，速动比率为 2.71。该公司的 50 日简单移动平均线为 34.58 美元，200 日简单移动平均线为 27.12 美元。</p>
</div><p>Travere Therapeutics (NASDAQ:TVTX - Get Free Report) last announced its earnings results on Thursday, October 30th. The company reported $0.28 earnings per share (EPS) for the quarter, topping analysts' consensus estimates of ($0.31) by $0.59. Travere Therapeutics had a negative net margin of 20.32% and a negative return on equity of 178.68%. The firm had revenue of $164.86 million for the quarter, compared to analyst estimates of $106.09 million. During the same quarter in the prior year, the business posted ($0.70) EPS. The business's revenue was up 162.1% compared to the same quarter last year. Analysts forecast that Travere Therapeutics, Inc. will post -1.4 earnings per share for the current year.</p>
<div class="lb-trans"><p>Travere Therapeutics（纳斯达克：TVTX - 获取免费报告）最近于 10 月 30 日（星期四）公布了其财报。公司报告本季度每股收益（EPS）为 0.28 美元，超出分析师一致预期的（0.31 美元）0.59 美元。Travere Therapeutics 的净利润率为-20.32%，股本回报率为-178.68%。该公司本季度的收入为 1.6486 亿美元，而分析师预期为 1.0609 亿美元。去年同期，该公司的每股收益为（0.70 美元）。与去年同期相比，该公司的收入增长了 162.1%。分析师预测 Travere Therapeutics, Inc.在当前年度的每股收益将为-1.4 美元。</p>
</div><h2>Institutional Investors Weigh In On Travere Therapeutics</h2>
<div class="lb-trans"><h2>机构投资者对 Travere Therapeutics 的看法</h2>
</div><ul>
<li>Travere Therapeutics Still On The Rise After Encouraging Data</li>
</ul>
<div class="lb-trans"><ul>
<li>Travere Therapeutics 在鼓舞人心的数据后仍在上升</li>
</ul>
</div><p>Several hedge funds have recently added to or reduced their stakes in TVTX. First Horizon Corp bought a new stake in shares of Travere Therapeutics in the 3rd quarter valued at about $36,000. Raymond James Financial Inc. bought a new position in shares of Travere Therapeutics in the 2nd quarter worth approximately $33,000. Mirae Asset Global Investments Co. Ltd. boosted its holdings in Travere Therapeutics by 26.2% in the 4th quarter. Mirae Asset Global Investments Co. Ltd. now owns 4,348 shares of the company's stock worth $166,000 after buying an additional 902 shares during the period. Headlands Technologies LLC bought a new stake in shares of Travere Therapeutics in the second quarter worth about $73,000. Finally, Wealth Enhancement Advisory Services LLC purchased a new stake in Travere Therapeutics in the 4th quarter worth about $224,000.</p>
<div class="lb-trans"><p>几家对冲基金最近增加或减少了对 TVTX 的持股。First Horizon Corp 在第三季度购买了价值约 36,000 美元的 Travere Therapeutics 新股份。Raymond James Financial Inc.在第二季度购买了价值约 33,000 美元的 Travere Therapeutics 新头寸。Mirae Asset Global Investments Co. Ltd.在第四季度将其在 Travere Therapeutics 的持股增加了 26.2%。Mirae Asset Global Investments Co. Ltd.现在拥有 4,348 股公司股票，价值 166,000 美元，此前在此期间又购买了 902 股。Headlands Technologies LLC 在第二季度购买了价值约 73,000 美元的 Travere Therapeutics 新股份。最后，Wealth Enhancement Advisory Services LLC 在第四季度购买了价值约 224,000 美元的 Travere Therapeutics 新股份。</p>
</div><h2>Analyst Upgrades and Downgrades</h2>
<div class="lb-trans"><h2>分析师的升级和降级</h2>
</div><p>A number of research firms recently commented on TVTX. Weiss Ratings reaffirmed a &#34;sell (e+)&#34; rating on shares of Travere Therapeutics in a research note on Wednesday, January 21st. Zacks Research cut shares of Travere Therapeutics from a &#34;strong-buy&#34; rating to a &#34;hold&#34; rating in a research report on Wednesday, November 12th. HC Wainwright reiterated a &#34;buy&#34; rating and set a $47.00 price target on shares of Travere Therapeutics in a research report on Friday, November 28th. Guggenheim reiterated a &#34;buy&#34; rating and issued a $49.00 price target on shares of Travere Therapeutics in a research note on Wednesday, January 14th. Finally, Wall Street Zen upgraded Travere Therapeutics from a &#34;buy&#34; rating to a &#34;strong-buy&#34; rating in a report on Saturday, December 13th. Twelve investment analysts have rated the stock with a Buy rating, three have issued a Hold rating and one has assigned a Sell rating to the company's stock. According to MarketBeat.com, Travere Therapeutics has a consensus rating of &#34;Moderate Buy&#34; and a consensus target price of $38.86.</p>
<div class="lb-trans"><p>几家研究公司最近对 TVTX 发表了评论。Weiss Ratings 在 1 月 21 日（星期三）的研究报告中重申了对 Travere Therapeutics 股票的 “卖出（e+）” 评级。Zacks Research 在 11 月 12 日（星期三）的研究报告中将 Travere Therapeutics 的股票评级从 “强力买入” 下调至 “持有”。HC Wainwright 在 11 月 28 日（星期五）的研究报告中重申了 “买入” 评级，并设定了 47.00 美元的目标价。Guggenheim 在 1 月 14 日（星期三）的研究报告中重申了 “买入” 评级，并对 Travere Therapeutics 的股票设定了 49.00 美元的目标价。最后，Wall Street Zen 在 12 月 13 日（星期六）的报告中将 Travere Therapeutics 的评级从 “买入” 升级为 “强力买入”。十二位投资分析师对该股票给予了买入评级，三位给予了持有评级，一位给予了卖出评级。根据 MarketBeat.com 的数据，Travere Therapeutics 的共识评级为 “适度买入”，共识目标价为 38.86 美元。</p>
</div><p><strong>View Our Latest Report on TVTX</strong></p>
<div class="lb-trans"><p><strong>查看我们关于 TVTX 的最新报告</strong></p>
</div><h2>About Travere Therapeutics</h2>
<div class="lb-trans"><h2>关于 Travere Therapeutics</h2>
</div><p>(Get Free Report)</p>
<div class="lb-trans"><p>（获取免费报告）</p>
</div><p>Travere Therapeutics, Inc NASDAQ: TVTX is a biopharmaceutical company headquartered in San Diego, California, dedicated to the development and commercialization of therapies for rare kidney and genetic disorders. The company's mission is to address unmet needs in conditions with limited treatment options by focusing on diseases that affect small patient populations. Travere combines research, development and commercial capabilities to bring innovative medicines to market.</p>
<div class="lb-trans"><p>Travere Therapeutics, Inc.（纳斯达克：TVTX）是一家总部位于加利福尼亚州圣地亚哥的生物制药公司，致力于开发和商业化针对罕见肾脏和遗传疾病的疗法。公司的使命是通过关注影响小型患者群体的疾病，解决治疗选择有限的疾病的未满足需求。Travere 结合了研究、开发和商业能力，将创新药物推向市场。</p>
</div><p>The company's lead product is sparsentan, a dual endothelin angiotensin receptor antagonist that has received accelerated approval from the U.S.</p>
<div class="lb-trans"><p>公司的主要产品是 sparsentan，这是一种双重内皮素 - 血管紧张素受体拮抗剂，已获得美国的加速批准。</p>
</div><h2>Read More</h2>
<div class="lb-trans"><h2>了解更多</h2>
</div><ul>
<li>Five stocks we like better than Travere Therapeutics</li>
<li>How a Family Trust May Be Able To Help Preserve Your Wealth</li>
<li>Do not delete, read immediately</li>
<li>NEW LAW: Congress Approves Setup For Digital Dollar?</li>
<li>“Fed Proof” Your Bank Account with THESE 4 Simple Steps</li>
<li>A U.S. “birthright” claim worth trillions - activated quietly</li>
</ul>
<div class="lb-trans"><ul>
<li>我们更看好的五只股票比 Travere Therapeutics 更好</li>
<li>家族信托如何帮助保护您的财富</li>
<li>请勿删除，立即阅读</li>
<li>新法律：国会批准数字美元的设立？</li>
<li>用这 4 个简单步骤 “防止” 您的银行账户受到影响</li>
<li>一项价值数万亿的美国 “出生权” 索赔 - 静悄悄地激活</li>
</ul>
</div><p><img src="https://imageproxy.pbkrs.com/https://www.marketbeat.com/scripts/InsiderTradesChart.ashx/query-UHJlZml4PU5BU0RBUSZTeW1ib2w9VFZUWA" alt="" original-src="https://www.marketbeat.com/scripts/InsiderTradesChart.ashx?Prefix=NASDAQ&amp;Symbol=TVTX"/></p>
<p><em>This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.</em></p>
<div class="lb-trans"><p><em>此即时新闻提醒由叙述科学技术和 MarketBeat 的金融数据生成，以便为读者提供最快的报道和公正的覆盖。请将任何问题或评论发送至 contact@marketbeat.com。</em></p>
</div><h2>Should You Invest $1,000 in Travere Therapeutics Right Now?</h2>
<div class="lb-trans"><h2>您现在应该投资 1,000 美元于 Travere Therapeutics 吗？</h2>
</div><p>Before you consider Travere Therapeutics, you'll want to hear this.</p>
<div class="lb-trans"><p>在您考虑 Travere Therapeutics 之前，您需要听听这个。</p>
</div><p>MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Travere Therapeutics wasn't on the list.</p>
<div class="lb-trans"><p>MarketBeat 每天跟踪华尔街顶级评级和表现最佳的研究分析师及其推荐的股票。MarketBeat 已识别出五只股票，顶级分析师正在悄悄地向客户推荐在更广泛的市场注意到之前立即购买……而 Travere Therapeutics 并不在名单上。</p>
</div><p>While Travere Therapeutics currently has a Moderate Buy rating among analysts, top-rated analysts believe these five stocks are better buys.</p>
<div class="lb-trans"><p>虽然 Travere Therapeutics 目前在分析师中获得了适度买入评级，但顶级分析师认为这五只股票更值得购买。</p>
</div><p>View The Five Stocks Here</p>
<div class="lb-trans"><p>在这里查看这五只股票</p>
</div>

Travere Therapeutics（NASDAQ:TVTX）的首席执行官出售了价值 244,131.35 美元的股票